Latin America, Middle East and Africa Cancer Immunotherapy Market Size to register a growth of 15.5% CAGR

20-11-2018 | Report Format: Electronic (PDF)

Growth, Trends and Report Highlights

According to a new report LAMEA Cancer Immunotherapy Market, published by KBV research, the LAMEA Cancer Immunotherapy Market would witness market growth of 15.5% CAGR during the forecast period (2018 – 2024).

The Brazil market would dominate the LAMEA Monoclonal Antibodies Cancer Immunotherapy Market by Country 2024; growing at a CAGR of 15.5 % during the forecast period. The Argentina market is expected to witness a CAGR of 17% during (2018 - 2024). Additionally, The UAE market is expected to witness a CAGR of 14.8% during (2018 - 2024).

The Lung Cancer market dominated the LAMEA Cancer Immunotherapy Market by Application 2017, thereby, achieving a market value of $2,602.8 million by 2024. The Melanoma market is expected to witness a CAGR of 17.2% during (2018 - 2024). Additionally, The Head & Neck Cancer market is expected to witness highest CAGR of 16.1% during (2018 - 2024).

The Hospitals market dominated the Saudi Arabia Cancer Immunotherapy Market by End User 2017, growing at a CAGR of 14.7 % during the forecast period. The Clinics market is expected to witness a CAGR of 14.3% during (2018 - 2024). Additionally, The Other End User market is expected to witness highest CAGR of 15% during (2018 - 2024).

Full Report: https://www.kbvresearch.com/lamea-cancer-immunotherapy-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd